Recent Updates
Recently added Catalysts

Surovatamig

Phase 3

Untreated Follicular Lymphoma | Small molecule | Oncology |AstraZeneca PLC|Last Updated: Jul 20, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment1,018
FDA Designations
No designations recorded
Clinical trial landscape

Surovatamig · 6 trials · 12 indications

Phase 3 2Phase 2 2Phase 1 2
NCT07509151Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
RECRUITING420 Analytics
NCT06549595A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsUntreated Follicular Lymphoma
RECRUITING1,018 Analytics
PHASE3RECRUITING
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHVUnlock trial analytics
PHASE3RECRUITING
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Untreated Follicular LymphomaUnlock trial analytics
Study Endpoints
Primary Endpoints
DOSRI- Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs)
Up to 5 years

To assess the safety and tolerability of SC surovatamig as consolidation therapy using dose optimisation in CLL/SLL participants with uIGHV. Also, to determine the RP3D of SC surovatamig monotherapy as consolidation therapy in CLL/SLL participants with uIGHV.

Phase III- Progression Free Survival (PFS)
Until disease progression or death (up to 5 years)

PFS is defined as the time from date of randomisation until disease progression or death due to any cause, whichever occur first based on International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria, as assessed by independent review committee (IRC).

DOSRI- Number of participants with study intervention discontinuations, dose reductions and dose delays due to AEs
Up to 5 years

To assess the safety and tolerability of SC surovatamig as consolidation therapy using dose optimisation in CLL/SLL participants with uIGHV. Also, to determine the RP3D of SC surovatamig monotherapy as consolidation therapy in CLL/SLL participants with uIGHV.

SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEs
Up to 10 years

Frequency, severity, and relationship to study drug of AEs and SAEs; dose modifications; changes in physical examination and safety procedures.

SRI Primary: Determination of the recommended Phase III dose (RP3D)
Up to 1 year

The RP3D will be the dose of Surovatamig selected for the Phase 3 part based on safety data compiled during the safety run-in part

Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
Up to 10 years

PFS, based on Lugano 2014 Response Criteria, as assessed by BICR.

Number of participants with adverse events.
Through study completion, an average of 2 years

To assess the safety and tolerability of surovatamig on adverse events, including Adverse events, Serious adverse events, Adverse event of special interests, and Adverse events leading to discontinuation of surovatamig.

Change from baseline in UPCR (from 24-hour urine collection or the intended 24-hour urine collection)
At 6 months

To assess the effect of surovatamig on proteinuria

Overall response rate (ORR) (central review)
Module 1: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 24 months. Module 2: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 12 months.

Overall response summarized via overall response rate (ORR), defined as the proportion of participants achieving either a Partial Response (PR) or Complete Response (CR) based on Lugano 2014 response criteria for non-Hodgkin Lymphoma, as determined by central review

Safety evaluation of surovatamig: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs)
Day 1 to end of the study (up to 52 weeks)

Number and percentage of participants with adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)

Safety evaluation of surovatamig: Frequency of dose limiting toxicities (DLTs).
Day 1 to end of the study (up to 52 weeks)

Number and percentage of participants with DLTs (dose-limiting toxicities) as defined in the study protocol

Safety of surovatamig: Incidence of AEs/SAEs leading to discontinuation of surovatamig
Day 1 to end of the study (up to 52 weeks)

Number of participants with AEs/SAEs leading to discontinuation of surovatamig

Tolerability of surovatamig: Incidence of treatment-related vital signs abnormalities
Day 1 to end of the study (up to 52 weeks)

Number and percentage of participants with treatment-related vital signs abnormalities

Tolerability of surovatamig: Incidence of treatment-related clinical laboratory abnormalities
Day 1 to end of the study (up to 52 weeks)

Number of participants with treatment-related clinical laboratory abnormalities

Tolerability of surovatamig: Number of participants with abnormal ECG
From baseline through Day 180.

Number and percentage of participants with abnormal ECG.

Number of Participants with Adverse Events, Serious Adverse Events and Adverse Events of Special Interest
Up to 6 years 4 months

Safety and tolerability of surovatamig as monotherapy and in combination with other anticancer agents across mature B-cell malignancies.

Number of Participants with Dose Limiting Toxicity (DLTs)
Up to 2 months

Safety and tolerability of surovatamig as monotherapy and in combination with other anticancer agents across mature B-cell malignancies.

Secondary Endpoints
Objective Response Rate (ORR)
Up to 5 years
Complete Response rate (CR rate)
Up to 5 years
Duration of response (DoR)
Up to 5 years
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Dose Optimisation and Safety run-in (DOSRI)- Surovatamig Dose 1EXPERIMENTALParticipants will receive Surovatamig Dose 1 subcutaneously (SC) for 6 cycles (each cycle is 28 days in length).
DOSRI-Surovatamig Dose 2EXPERIMENTALParticipants will receive Surovatamig Dose 2 SC for 6 cycles (each cycle is 28 days in length).
Phase III-Arm A: Surovatamig SCEXPERIMENTALParticipants will receive Surovatamig at RP3D subcutaneously for 6 cycles (each cycle is 28 days in length).
Phase III-Arm B: ObservationNO_INTERVENTIONParticipants will undergo observation for 24 weeks.
Rituximab, Surovatamig - AEXPERIMENTALSurovatamig regimen A plus rituximab
Rituximab, Surovatamig - BEXPERIMENTALSurovatamig regimen B plus rituximab
ChemoimmunotherapyACTIVE_COMPARATORInvestigator's choice between 3 standard immunochemotherapy regimen (R-CHOP, R-CVP, or B-R followed by rituximab maintenance)
Surovatamig ArmEXPERIMENTALParticipants will receive Surovatamig
Module 1: Surovatamig Monotherapy in Participants with Relapsed or Refractory Follicular LymphomaEXPERIMENTALIn Module 1, the efficacy and safety of surovatamig at the RP2D will be evaluated in R/R FL. Surovatamig will be administered as intravenous infusion.
Module 2: Surovatamig Monotherapy in Participants with Relapsed or Refractory LBCLEXPERIMENTALIn Module 2, the efficacy and safety of surovatamig at the RP2D will be evaluated in R/R LBCL. Surovatamig will be administered as intravenous infusion.
SurovatamigEXPERIMENTALParticipants will receive Surovatamig subcutaneously in one of three dosing regimens: once (Part 1), twice (Part 2), or three times (Part 3), depending on the study part.
Substudy 1 (RR CLL/SLL): Cohort 1A (Surovatamig Monotherapy)EXPERIMENTALParticipants will receive surovatamig monotherapy as subcutaneous (SC) injection.
Substudy 1 (RR CLL/SLL): Cohort 1B (Surovatamig + Acalabrutinib)EXPERIMENTALParticipants will receive surovatamig as SC injection. Participants will receive acalabrutinib tablet orally twice daily.
Substudy 1 (RR CLL/SLL): Cohort 1C (Surovatamig Monotherapy)EXPERIMENTALParticipants will receive surovatamig monotherapy as intravenous (IV) infusion.
Substudy 2 (RR MCL): Cohort 2A (Surovatamig Monotherapy)EXPERIMENTALParticipants will receive surovatamig monotherapy as SC injection.
Substudy 2 (RR MCL): Cohort 2C (Surovatamig Monotherapy)EXPERIMENTALParticipants will receive surovatamig monotherapy as IV infusion.
Substudy 3 (LBCL): Cohort 3A 2SUD (Surovatamig + RCHOP)EXPERIMENTALParticipants will receive surovatamig as IV infusion with a 2SUD (double step-up dosing) schedule for priming in combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.
Substudy 3 (LBCL): Cohort 3B 3SUD (Surovatamig + RCHOP)EXPERIMENTALParticipants will receive surovatamig as IV infusion with a 3SUD (triple step-up dosing) schedule for priming in combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.
Interventions
NameTypeDescription
SurovatamigDRUGSurovatamig will be administered as a subcutaneous injection.
R-CHOPDRUGRituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
R-CVPDRUGRituximab, Cyclophosphamide, Vincristine and Prednisone
BRDRUGBendamustine, Rituximab
Prednisone (or equivalent)DRUGPrednisone (or equivalent) will be administered either oral or IV infusion as per standard of care.
RituximabDRUGRituximab will be administered as IV infusion as per standard of care.
CyclophosphamideDRUGCyclophosphamide will be administered as IV infusion as per standard of care.
VincristineDRUGVincristine will be administered as IV infusion as per standard of care.
DoxorubicinDRUGDoxorubicin will be administered as IV infusion as per standard of care.
AcalabrutinibDRUGAcalabrutinib will be administered orally
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 18 Years
SexALL
Healthy VolunteersNo
Study Sites30

Inclusion Criteria: * Documented diagnosis of CLL/SLL with genomic features defined by unmutated IGHV. * Treatment received and response at the end of 1L (first-line) finite therapy. * Participants with SLL (except those in CR in Phase III part) must have measurable disease (nodal or extranodal) wi...

Countries:AustraliaCanadaTurkey (Türkiye)United KingdomUnited StatesBelgiumBrazilChinaCzechiaDenmarkFinlandGermanyHong KongHungaryIndiaJapanPolandPuerto RicoSouth KoreaSpainSwedenTaiwanThailandFranceItalyUkraine
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJul 20, 2026NCT06549595lastUpdatePostDate: changed
MEDIUMJul 20, 2026NCT06564038primaryCompletionDate: changed
LOWJul 20, 2026NCT06549595lastUpdatePostDate: changed
MEDIUMJul 20, 2026NCT06564038primaryCompletionDate: changed
LOWJul 9, 2026NCT07509151lastUpdatePostDate: changed
LOWJul 9, 2026NCT07509151lastUpdatePostDate: changed
LOWJul 2, 2026NCT07571746lastUpdatePostDate: changed
LOWJul 2, 2026NCT07201558lastUpdatePostDate: changed
LOWJul 2, 2026NCT07571746lastUpdatePostDate: changed
LOWJul 2, 2026NCT07201558lastUpdatePostDate: changed
LOWJul 2, 2026NCT07571746lastUpdatePostDate: changed
LOWJul 2, 2026NCT07571746lastUpdatePostDate: changed
MEDIUMJun 25, 2026NCT06526793Enrollment: 240 → 270
MEDIUMJun 25, 2026NCT06526793Enrollment: 240 → 270
MEDIUMJun 25, 2026NCT06526793Enrollment: 240 → 270
LOWJun 23, 2026NCT06549595lastUpdatePostDate: changed
LOWJun 23, 2026NCT06549595lastUpdatePostDate: changed
LOWJun 10, 2026NCT06564038lastUpdatePostDate: changed
LOWJun 10, 2026NCT06564038lastUpdatePostDate: changed
LOWJun 2, 2026NCT07509151Status: NOT_YET_RECRUITING → RECRUITING